3D model 2-Methyl-5-nitro-2H-indazole, CAS 5228-48-8, molecular formula C8H7N3O2, molar mass 177.16 g/mol
About 2-Methyl-5-nitro-2H-indazole
2-Methyl-5-nitro-2H-indazole is a chemical compound registered under number CAS 5228-48-8, with the molecular formula C8H7N3O2, and a molar mass of 177.16 g/mol.
The molecule contains 20 atoms connected by 21 chemical bonds. The full systematic IUPAC name of this compound is 2-methyl-5-nitroindazole. The interactive 3D model above lets you view the spatial arrangement of the atoms — you can rotate it with the mouse, zoom with the scroll wheel, and switch between skeletal / Ball & Stick / Space Fill visualization modes.
In terms of physicochemical properties, the partition coefficient logP = 1.8 (positive value, a lipophilic compound), polar surface area PSA = 63.6 Ų, 0 donors and 3 hydrogen bond acceptors. These parameters are key when assessing bioavailability and interaction with biomolecules.
Chemical data for this compound comes from PubChem (NIH NLM NCBI), one of the world's largest chemical databases. All information is updated automatically and enriched with GHS hazard statement translations compliant with the CLP Regulation (EC 1272/2008). The widget above may be used for educational, research and commercial purposes.
P. Lanzetta, J. Korobelnik, J. Heier et al. (2024) · The Lancet
AI Summary Aflibercept 8 mg showed efficacy and safety with extended dosing intervals, which has the potential to improve the management of patients with nAMD.
Matt Hickey, Nathanael Gistand, Janet Grochowski et al. (2024) · Clinical Infectious Diseases
AI Summary LA ART can be an important tool for improving viral suppression among patients who face adherence challenges to oral ART, and was seen in 92%.
Liana K. Billings, Stanley H. Hsia, H. Bays et al. (2025) · The Lancet
AI Summary Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment.
R. Panaccione, B. Feagan, Anita Afzali et al. (2025) · The Lancet
AI Summary Both guselkumab regimens were superior to placebo for the endpoint of clinical response at week 12 and clinical remission at week 48 in GALAXI-2 and GALAXI-3.
AI Summary It can be seen that, in fact, the low-carbohydrate diet still has an advantage over the other diets, even though this group consumed more calories, and this clear difference between the diets is the most obvious and noteworthy result.
Muharam Ali Shah, Qurban Ali Shah Syed, Imtiaz Ali Laghari et al. (2026) · 2026 5th International Conference on Computing, Mathematics and Engineering Technologies (iCoMET)
Dane z PubMed (NIH NLM), OpenAlex (CC0), Semantic Scholar (AI2). AI Summary wygenerowane przez Semantic Scholar TLDR. Artykuły z ikoną wymagają płatnego dostępu.